Interleukin 2 (Vietnamese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Interleukin 2" in Vietnamese language version.

refsWebsite

Global rank Vietnamese rank

30nih.gov

4^th place

7^th place

20doi.org

2^nd place

2nytimes.com

7^th place

23^rd place

2archive.org

6^th place

4^th place

1ensembl.org

1,626^th place

4,690^th place

1cancernetwork.com

low place

1businessweek.com

712^th place

567^th place

1neoleukin.com

low place

1cancer.org

3,680^th place

4,182^nd place

1web.archive.org

1^st place

1worldcat.org

5^th place

13^th place

1fda.gov

447^th place

625^th place

1scielo.br

1,606^th place

3,632^nd place

1the-scientist.com

7,827^th place

4,097^th place

1genome.jp

low place

1swissinfo.ch

1,485^th place

3,765^th place

1thepharmaletter.com

low place

archive.org

Paul WE (2008). Fundamental immunology (ấn bản thứ 6). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. ISBN 978-0-7817-6519-0.
Welte K, Wang CY, Mertelsmann R, Venuta S, Feldman SP, Moore MA (tháng 8 năm 1982). “Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity”. The Journal of Experimental Medicine. 156 (2): 454–64. doi:10.1084/jem.156.2.454. PMC 2186775. PMID 6980256.

businessweek.com

investing.businessweek.com

Bloombert BusinessWeek. Last updated ngày 3 tháng 3 năm 2014 Shenzhen Neptunus Interlng-H

cancer.org

American Cancer Society. Interleukin-2 (Aldesleukin) Lưu trữ 2015-02-12 tại Wayback Machine. Date accessed: 07 Nov 10.

cancernetwork.com

Bhatia S, Tykodi SS, Thompson JA (tháng 5 năm 2009). “Treatment of metastatic melanoma: an overview”. Oncology. 23 (6): 488–96. PMC 2737459. PMID 19544689.

doi.org

Arenas-Ramirez N, Woytschak J, Boyman O (tháng 12 năm 2015). “Interleukin-2: Biology, Design and Application”. Trends in Immunology. 36 (12): 763–777. doi:10.1016/j.it.2015.10.003. PMID 26572555.
Liao W, Lin JX, Leonard WJ (tháng 10 năm 2011). “IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation”. Current Opinion in Immunology. 23 (5): 598–604. doi:10.1016/j.coi.2011.08.003. PMC 3405730. PMID 21889323.
Wang X, Rickert M, Garcia KC (tháng 11 năm 2005). “Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors”. Science. 310 (5751): 1159–63. doi:10.1126/science.1117893. PMID 16293754.
Gaffen SL, Liu KD (tháng 11 năm 2004). “Overview of interleukin-2 function, production and clinical applications”. Cytokine. 28 (3): 109–23. doi:10.1016/j.cyto.2004.06.010. PMID 15473953.
Friedmann MC, Migone TS, Russell SM, Leonard WJ (tháng 3 năm 1996). “Different interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferation”. Proceedings of the National Academy of Sciences of the United States of America. 93 (5): 2077–82. doi:10.1073/pnas.93.5.2077. PMC 39912. PMID 8700888.
Liao W, Lin JX, Leonard WJ (tháng 1 năm 2013). “Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy”. Immunity. 38 (1): 13–25. doi:10.1016/j.immuni.2013.01.004. PMC 3610532. PMID 23352221.
Malek TR, Castro I (tháng 8 năm 2010). “Interleukin-2 receptor signaling: at the interface between tolerance and immunity”. Immunity. 33 (2): 153–65. doi:10.1016/j.immuni.2010.08.004. PMC 2946796. PMID 20732639.
Reich A, Szepietowski JC (2007). “Mediators of pruritus in psoriasis”. Mediators of Inflammation. 2007: 1–6. doi:10.1155/2007/64727. PMC 2221678. PMID 18288273.
Noble S, Goa KL (tháng 5 năm 1997). “Aldesleukin (recombinant interleukin-2)”. BioDrugs. 7 (5): 394–422. doi:10.2165/00063030-199707050-00007. PMID 18031103.
Silva DA, Yu S, Ulge UY, Spangler JB, Jude KM, Labão-Almeida C, Ali LR, Quijano-Rubio A, Ruterbusch M, Leung I, Biary T, Crowley SJ, Marcos E, Walkey CD, Weitzner BD, Pardo-Avila F, Castellanos J, Carter L, Stewart L, Riddell SR, Pepper M, Bernardes GJ, Dougan M, Garcia KC, Baker D (tháng 1 năm 2019). “De novo design of potent and selective mimics of IL-2 and IL-15”. Nature. 565 (7738): 186–191. doi:10.1038/s41586-018-0830-7. PMID 30626941.
Shi VY, Tran K, Patel F, Leventhal J, Konia T, Fung MA, Wilken R, Garcia MS, Fitzmaurice SD, Joo J, Monjazeb AM, Burrall BA, King B, Martinez S, Christensen SD, Maverakis E (tháng 10 năm 2015). “100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series”. Journal of the American Academy of Dermatology. 73 (4): 645–54. doi:10.1016/j.jaad.2015.06.060. PMID 26259990.
Shaker MA, Younes HM (tháng 7 năm 2009). “Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy”. Journal of Pharmaceutical Sciences. 98 (7): 2268–98. doi:10.1002/jps.21596. PMID 19009549.
“Correction for Krieg et al., Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells”. Proceedings of the National Academy of Sciences. 109 (1): 345. ngày 28 tháng 12 năm 2011. doi:10.1073/pnas.1119897109. ISSN 0027-8424. PMC 3252892.
Figgitt DP, Lamb HM, Goa KL (2000). “Denileukin diftitox”. American Journal of Clinical Dermatology. 1 (1): 67–72, discussion 73. doi:10.2165/00128071-200001010-00008. PMID 11702307.
Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, Rosenzwajg M, Bernard C, Klatzmann D (tháng 12 năm 2013). “Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial”. The Lancet. Diabetes & Endocrinology. 1 (4): 295–305. doi:10.1016/S2213-8587(13)70113-X. PMID 24622415.
Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J (tháng 3 năm 2006). “Selective stimulation of T cell subsets with antibody-cytokine immune complexes”. Science. 311 (5769): 1924–7. doi:10.1126/science.1122927. PMID 16484453.
Chavez AR, Buchser W, Basse PH, Liang X, Appleman LJ, Maranchie JK, Zeh H, de Vera ME, Lotze MT (tháng 12 năm 2009). “Pharmacologic administration of interleukin-2”. Annals of the New York Academy of Sciences. 1182: 14–27. doi:10.1111/j.1749-6632.2009.05160.x. PMID 20074271.
Welte K, Wang CY, Mertelsmann R, Venuta S, Feldman SP, Moore MA (tháng 8 năm 1982). “Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity”. The Journal of Experimental Medicine. 156 (2): 454–64. doi:10.1084/jem.156.2.454. PMC 2186775. PMID 6980256.
Almeida, Hugo (April–June 2011). “Drugs obtained by biotechnology processing” (PDF). Brazilian Journal of Pharmaceutical Sciences. 47 (2): 199–207. doi:10.1590/s1984-82502011000200002.
Whittington R, Faulds D (tháng 9 năm 1993). “Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer”. Drugs. 46 (3): 446–514. doi:10.2165/00003495-199346030-00009. PMID 7693434.

ensembl.org

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000109471 - Ensembl, May 2017

fda.gov

“Changes in the Ontak (denileukin diftitiox)”. Package Insert to Include a Description of Ophthalmologic Adverse Events ]. FDA. ngày 11 tháng 5 năm 2009.

genome.jp

“D02749 (Teceleukin)”. KEGG drug.

neoleukin.com

“Neoleukin Therapeutics”. neoleukin.com. Truy cập ngày 14 tháng 1 năm 2019.

nih.gov

pubmed.ncbi.nlm.nih.gov

Arenas-Ramirez N, Woytschak J, Boyman O (tháng 12 năm 2015). “Interleukin-2: Biology, Design and Application”. Trends in Immunology. 36 (12): 763–777. doi:10.1016/j.it.2015.10.003. PMID 26572555.
Liao W, Lin JX, Leonard WJ (tháng 10 năm 2011). “IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation”. Current Opinion in Immunology. 23 (5): 598–604. doi:10.1016/j.coi.2011.08.003. PMC 3405730. PMID 21889323.
Wang X, Rickert M, Garcia KC (tháng 11 năm 2005). “Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors”. Science. 310 (5751): 1159–63. doi:10.1126/science.1117893. PMID 16293754.
Gaffen SL, Liu KD (tháng 11 năm 2004). “Overview of interleukin-2 function, production and clinical applications”. Cytokine. 28 (3): 109–23. doi:10.1016/j.cyto.2004.06.010. PMID 15473953.
Friedmann MC, Migone TS, Russell SM, Leonard WJ (tháng 3 năm 1996). “Different interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferation”. Proceedings of the National Academy of Sciences of the United States of America. 93 (5): 2077–82. doi:10.1073/pnas.93.5.2077. PMC 39912. PMID 8700888.
Liao W, Lin JX, Leonard WJ (tháng 1 năm 2013). “Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy”. Immunity. 38 (1): 13–25. doi:10.1016/j.immuni.2013.01.004. PMC 3610532. PMID 23352221.
Malek TR, Castro I (tháng 8 năm 2010). “Interleukin-2 receptor signaling: at the interface between tolerance and immunity”. Immunity. 33 (2): 153–65. doi:10.1016/j.immuni.2010.08.004. PMC 2946796. PMID 20732639.
Reich A, Szepietowski JC (2007). “Mediators of pruritus in psoriasis”. Mediators of Inflammation. 2007: 1–6. doi:10.1155/2007/64727. PMC 2221678. PMID 18288273.
Noble S, Goa KL (tháng 5 năm 1997). “Aldesleukin (recombinant interleukin-2)”. BioDrugs. 7 (5): 394–422. doi:10.2165/00063030-199707050-00007. PMID 18031103.
Bhatia S, Tykodi SS, Thompson JA (tháng 5 năm 2009). “Treatment of metastatic melanoma: an overview”. Oncology. 23 (6): 488–96. PMC 2737459. PMID 19544689.
Silva DA, Yu S, Ulge UY, Spangler JB, Jude KM, Labão-Almeida C, Ali LR, Quijano-Rubio A, Ruterbusch M, Leung I, Biary T, Crowley SJ, Marcos E, Walkey CD, Weitzner BD, Pardo-Avila F, Castellanos J, Carter L, Stewart L, Riddell SR, Pepper M, Bernardes GJ, Dougan M, Garcia KC, Baker D (tháng 1 năm 2019). “De novo design of potent and selective mimics of IL-2 and IL-15”. Nature. 565 (7738): 186–191. doi:10.1038/s41586-018-0830-7. PMID 30626941.
Shi VY, Tran K, Patel F, Leventhal J, Konia T, Fung MA, Wilken R, Garcia MS, Fitzmaurice SD, Joo J, Monjazeb AM, Burrall BA, King B, Martinez S, Christensen SD, Maverakis E (tháng 10 năm 2015). “100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series”. Journal of the American Academy of Dermatology. 73 (4): 645–54. doi:10.1016/j.jaad.2015.06.060. PMID 26259990.
Shaker MA, Younes HM (tháng 7 năm 2009). “Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy”. Journal of Pharmaceutical Sciences. 98 (7): 2268–98. doi:10.1002/jps.21596. PMID 19009549.
Figgitt DP, Lamb HM, Goa KL (2000). “Denileukin diftitox”. American Journal of Clinical Dermatology. 1 (1): 67–72, discussion 73. doi:10.2165/00128071-200001010-00008. PMID 11702307.
Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, Rosenzwajg M, Bernard C, Klatzmann D (tháng 12 năm 2013). “Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial”. The Lancet. Diabetes & Endocrinology. 1 (4): 295–305. doi:10.1016/S2213-8587(13)70113-X. PMID 24622415.
Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J (tháng 3 năm 2006). “Selective stimulation of T cell subsets with antibody-cytokine immune complexes”. Science. 311 (5769): 1924–7. doi:10.1126/science.1122927. PMID 16484453.
Chavez AR, Buchser W, Basse PH, Liang X, Appleman LJ, Maranchie JK, Zeh H, de Vera ME, Lotze MT (tháng 12 năm 2009). “Pharmacologic administration of interleukin-2”. Annals of the New York Academy of Sciences. 1182: 14–27. doi:10.1111/j.1749-6632.2009.05160.x. PMID 20074271.
Welte K, Wang CY, Mertelsmann R, Venuta S, Feldman SP, Moore MA (tháng 8 năm 1982). “Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity”. The Journal of Experimental Medicine. 156 (2): 454–64. doi:10.1084/jem.156.2.454. PMC 2186775. PMID 6980256.
Whittington R, Faulds D (tháng 9 năm 1993). “Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer”. Drugs. 46 (3): 446–514. doi:10.2165/00003495-199346030-00009. PMID 7693434.
Dutcher JP (tháng 11 năm 2002). “Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma”. Oncology. 16 (11 Suppl 13): 4–10. PMID 12469934.

ncbi.nlm.nih.gov

“Human PubMed Reference:”.
Liao W, Lin JX, Leonard WJ (tháng 10 năm 2011). “IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation”. Current Opinion in Immunology. 23 (5): 598–604. doi:10.1016/j.coi.2011.08.003. PMC 3405730. PMID 21889323.
Friedmann MC, Migone TS, Russell SM, Leonard WJ (tháng 3 năm 1996). “Different interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferation”. Proceedings of the National Academy of Sciences of the United States of America. 93 (5): 2077–82. doi:10.1073/pnas.93.5.2077. PMC 39912. PMID 8700888.
Liao W, Lin JX, Leonard WJ (tháng 1 năm 2013). “Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy”. Immunity. 38 (1): 13–25. doi:10.1016/j.immuni.2013.01.004. PMC 3610532. PMID 23352221.
Malek TR, Castro I (tháng 8 năm 2010). “Interleukin-2 receptor signaling: at the interface between tolerance and immunity”. Immunity. 33 (2): 153–65. doi:10.1016/j.immuni.2010.08.004. PMC 2946796. PMID 20732639.
Reich A, Szepietowski JC (2007). “Mediators of pruritus in psoriasis”. Mediators of Inflammation. 2007: 1–6. doi:10.1155/2007/64727. PMC 2221678. PMID 18288273.
Bhatia S, Tykodi SS, Thompson JA (tháng 5 năm 2009). “Treatment of metastatic melanoma: an overview”. Oncology. 23 (6): 488–96. PMC 2737459. PMID 19544689.
“Correction for Krieg et al., Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells”. Proceedings of the National Academy of Sciences. 109 (1): 345. ngày 28 tháng 12 năm 2011. doi:10.1073/pnas.1119897109. ISSN 0027-8424. PMC 3252892.
Welte K, Wang CY, Mertelsmann R, Venuta S, Feldman SP, Moore MA (tháng 8 năm 1982). “Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity”. The Journal of Experimental Medicine. 156 (2): 454–64. doi:10.1084/jem.156.2.454. PMC 2186775. PMID 6980256.

nih.gov

“IL-2 Immunotherapy Fails to Benefit HIV-Infected Individuals Already Taking Antiretrovirals”. News Release. National Institutes of Health (NIH). ngày 10 tháng 2 năm 2009.

nytimes.com

Pollack A (ngày 31 tháng 7 năm 1990). “Cetus Drug Is Blocked By F.D.A.”. New York Times. This source mentions approval in 9 European countries.
Pollack, Andrew (ngày 23 tháng 7 năm 1991). “2 Biotech Pioneers To Merge”. New York Times.

scielo.br

Almeida, Hugo (April–June 2011). “Drugs obtained by biotechnology processing” (PDF). Brazilian Journal of Pharmaceutical Sciences. 47 (2): 199–207. doi:10.1590/s1984-82502011000200002.

swissinfo.ch

“Chiron shareholders approve Novartis deal”. SWI swissinfo.ch. 19 tháng 4 năm 2006.

the-scientist.com

Lehrman, Sally (ngày 20 tháng 1 năm 1992). “Cetus: A Collision Course With Failure”. The Scientist Magazine.

thepharmaletter.com

“Novartis sells rights to Proleukin in the USA to Prometheus; gets license for vaccine from IIG; and pleads guilty over Trileptal”. Pharmaletter. ngày 27 tháng 1 năm 2010.

web.archive.org

American Cancer Society. Interleukin-2 (Aldesleukin) Lưu trữ 2015-02-12 tại Wayback Machine. Date accessed: 07 Nov 10.

worldcat.org

“Correction for Krieg et al., Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells”. Proceedings of the National Academy of Sciences. 109 (1): 345. ngày 28 tháng 12 năm 2011. doi:10.1073/pnas.1119897109. ISSN 0027-8424. PMC 3252892.